Volume 26, Number 2—February 2020
Dispatch
Mycoplasma genitalium Antimicrobial Resistance in Community and Sexual Health Clinic Patients, Auckland, New Zealand
Anna Vesty, Gary McAuliffe, Sally Roberts, Gillian Henderson, and Indira Basu
Table 1
Prevalence of antimicrobial resistance in Mycoplasma genitalium strains from community and SHC patients, Auckland, New Zealand, 2017*
| Genotypic-resistance profile | Frequency, % |
||||||
|---|---|---|---|---|---|---|---|
| Mutation |
Community patients | SHC patients | All patients | ||||
| 23S rRNA | parC | gyrA | |||||
| Wild type | – | – | – | 20.8 | 24.2 | 22.2 | |
| Macrolide | + | – | – | 60.4 | 48.5 | 55.6 | |
| Macrolide + fluoroquinolone | + | + | – | 12.5 | 12.1 | 12.3 | |
| Macrolide + fluoroquinolone | + | + | + | 2.1 | 15.1 | 7.4 | |
| Fluoroquinolone | – | + | – | 4.2 | 0 | 2.5 | |
*SHC, sexual health clinic; +, positive; –, negative.
Page created: January 20, 2020
Page updated: January 20, 2020
Page reviewed: January 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.